Abstract | BACKGROUND/AIMS: METHODOLOGY: We retrospectively examined 17 patients with biopsy-proven NASH who received vitamin E at a dose of 300 mg/day for >=2 yr, and underwent second liver biopsies after treatment. Variables were compared between patients with (group R) and without (group NR) fibrosis regression. RESULTS: The median interval between basal and second liver biopsies was 2.4 yr (range, 2.0-5.8 yr). Overall, transaminase activities, insulin resistance index, and hepatic fibrosis markers were significantly improved. Although histological steatosis, inflammation, and fibrosis did not change after treatment, liver fibrosis improved in seven patients (41.2%), progressed in five (29.4%), and remained unchanged in five (29.4%). At baseline, subjects in group R (n = 7) were more likely to have diabetes, insulin resistance, and severe fibrosis compared to those in group NR (n = 10). Lower NAFLD activity score and larger decrease of ALT and insulin resistance after treatment were observed in group R compared with group NR. CONCLUSIONS:
|
Authors | Yoshio Sumida, Yuji Naito, Saiyu Tanaka, Kyoko Sakai, Yutaka Inada, Hiroyoshi Taketani, Kazuyuki Kanemasa, Kohichiroh Yasui, Yoshito Itoh, Takeshi Okanoue, Toshikazu Yoshikawa |
Journal | Hepato-gastroenterology
(Hepatogastroenterology)
Vol. 60
Issue 126
Pg. 1445-50
(Sep 2013)
ISSN: 0172-6390 [Print] Greece |
PMID | 23933938
(Publication Type: Journal Article)
|
Chemical References |
- Antioxidants
- Vitamin E
- Alanine Transaminase
|
Topics |
- Aged
- Aged, 80 and over
- Alanine Transaminase
(blood)
- Antioxidants
(therapeutic use)
- Fatty Liver
(drug therapy)
- Female
- Humans
- Insulin Resistance
- Male
- Middle Aged
- Non-alcoholic Fatty Liver Disease
- Retrospective Studies
- Time Factors
- Vitamin E
(therapeutic use)
|